---
title: "Progyny, Inc. 1Q 2026: Revenue $328.5M, EPS $0.29— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285728505.md"
description: "Progyny, Inc. reported its first-quarter 2026 results, showing revenue of $328.5M, a net income of $24.23M, and diluted EPS of $0.29, compared to $324.04M, $15.06M, and $0.17 in the same quarter last year. Revenue increased by 1.4% year-over-year, with membership growing to approximately 7.2M. The gross margin improved to 25.3%. The company also launched new women's health offerings and completed a $200M share repurchase program."
datetime: "2026-05-08T12:51:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285728505.md)
  - [en](https://longbridge.com/en/news/285728505.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285728505.md)
---

# Progyny, Inc. 1Q 2026: Revenue $328.5M, EPS $0.29— 10-Q Summary

Progyny, Inc. reported first-quarter 2026 results with revenue of $328.5M, net income of $24.23M and diluted EPS of $0.29, versus $324.04M, $15.06M and $0.17 in the year‑ago quarter respectively.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$328.5M

$324.04M

1.4%

Net income²

$24.23M

$15.06M

60.9%

Diluted EPS³

$0.29

$0.17

70.6%

_¹ Reported as “Revenue”. ² Reported as “Net income”. ³ Reported as “income per share”._

**Business Highlights**

-   Revenue rose 1% year over year to $328.5M, supported by growth in clients and covered lives despite a large client non‑renewal.
-   Membership expanded to about 7.2M; assisted reproductive technology (ART) cycles declined slightly to 15,647 from 16,160 while utilization rates increased modestly.
-   Gross margin improved 190 basis points to 25.3%, driven by care delivery efficiencies and lower stock‑based compensation expense.
-   Customer satisfaction and clinical outcomes remained strong, with member NPS scores of +81 for fertility and +79 for Progyny Rx, and outcomes above national averages.
-   Company pursued diversification with roughly 40+ new industry additions, launched expanded women's health offerings and completed a $200M share repurchase program.

Original SEC Filing: Progyny, Inc. \[ PGNY \] - 10-Q - May. 08, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PGNY.US](https://longbridge.com/en/quote/PGNY.US.md)

## Related News & Research

- [Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report | PGNY Stock News](https://longbridge.com/en/news/283875551.md)
- [Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference | PGNY Stock News](https://longbridge.com/en/news/285964121.md)
- [Forum Markets GAAP EPS of $0.06 beats by $0.28, revenue of $2.9M beats by $1.5M](https://longbridge.com/en/news/286415134.md)
- [Progyny Earnings Call Signals Confident, Profitable Growth](https://longbridge.com/en/news/285787043.md)
- [Is Progyny (PGNY) Pricing Reflect Its DCF Upside After Recent Share Price Rebound](https://longbridge.com/en/news/285319388.md)